Cancer clinical trials in the region Pays de la Loire
433 currently recruiting clinical trials
Looking for clinical trials?
Clinical trial search is a complex process, with countless criteria to consider. Our AI assistant navigates this complexity with precise, expert-level analysis of the most relevant trials based on your medical profile. Our database is fully up to date, so you see only actively recruiting sites. It's fast and easy:
- Create your account
- Copy-paste your latest medical report
- Our AI-based assistant does the rest for you
Whether you are a patient or a doctor, create an account to find and apply for the most relevant clinical trials:
Phase 1 / Phase 2
Breast cancer
Lung cancer
Prostate cancer
Liver and bile duct cancer
Bladder / Urinary Tract / Urethral cancer
Stomach and esophageal cancer
Endometrial cancer
Ovarian / Fallopian tubes / Peritoneum cancer
Head and neck cancer
Sarcoma and GIST
Thymus cancer
Penile cancer and germ cell tumors
Cervical / Vulvar / Vaginal cancer
Small intestine and appendix cancer
Thyroid and adrenal gland cancer
Brain tumors / Central nervous system tumors
Skin cancer
#NCT05706129
#2023-504254-35-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Squamous NSCLC
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced
Metastatic
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
8 recruiting sites
Debiopharm International SA
Phase 1 / Phase 2
Prostate cancer
#NCT04104776
#2023-508002-20-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Novartis
Phase 1 / Phase 2
Bladder / Urinary Tract / Urethral cancer
#NCT04104776
#2023-508002-20-00
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Novartis
Phase 1 / Phase 2
Endometrial cancer
#NCT04104776
#2023-508002-20-00
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Novartis
Phase 1 / Phase 2
Lung cancer
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT04104776
#2023-508002-20-00
Required histologic types
Mesothelium
Primary peritoneal cancer (PPC)
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Novartis
Phase 1 / Phase 2
Lymphoma
#NCT04104776
#2023-508002-20-00
Required histologic types
B cell lymphoma
T cell lymphoma
Required histologic sub types
Large B cell lymphoma
Peripheral T cell lymphoma
Required central nervous system lesions
None
Treated / Controled
Required number of previous lines of therapy
1
2
3 or more
Excluded previous treatments
Systemic Treatment-Naive
Allogeneic stem cell transplant
6 recruiting sites
Novartis
Phase 1 / Phase 2
Endometrial cancer
#NCT04104776
#2023-508002-20-00
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Excluded genetic anomalies
ARID1A
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Novartis
Phase 1 / Phase 2
Ovarian / Fallopian tubes / Peritoneum cancer
#NCT04104776
#2023-508002-20-00
Required histologic types
Epithelial ovarian cancer
Required histologic sub types
Clear cell carcinoma
Required disease stage
Locally Advanced
Metastatic
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Novartis
Phase 1 / Phase 2
Prostate cancer
#NCT04104776
#2023-508002-20-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
2
3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
7 recruiting sites
Novartis
Phase 1 / Phase 2
Multiple myeloma
#NCT06953960
#2024-517140-65-00
Sous étude 1 Escalade de dose
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required genetic anomalies
t(11;14)
Required number of previous lines of therapy
3 or more
Required previous treatments
Monoclonal antibodies
Proteasome inhibitor
Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Abbvie